Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104566
Filing Date
2025-08-07
Accepted
2025-08-07 07:30:52
Documents
90
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sabs-20250630.htm   iXBRL 10-Q 3014623
2 EX-31.1 sabs-ex31_1.htm EX-31.1 26641
3 EX-31.2 sabs-ex31_2.htm EX-31.2 26722
4 EX-32.1 sabs-ex32_1.htm EX-32.1 11392
5 EX-32.2 sabs-ex32_2.htm EX-32.2 11735
  Complete submission text file 0000950170-25-104566.txt   13158799

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20250630.xsd EX-101.SCH 1839108
93 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20250630_htm.xml XML 2598933
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)